Trump Executive Order on Psychedelic Drug Fast-Track
2 videos · score: 3,379 · first seen Jun 15, 2026
On April 18th, the Trump administration issued an executive order fast-tracking FDA approval for psychedelic drugs to treat mental illness, granting priority review vouchers to three companies — while CNBC highlights concerns from scientists about rushed approval risks, and unrelatedly, Snazzy Labs criticizes the Trump T1 smartphone as a misleading, poorly made product — the psychedelic policy is gaining attention for its potential impact on mental health treatment and regulatory precedent.
Why Trump Is Pushing Psychedelics To Treat Mental Illness
Trump’s April 18th executive order issuing priority FDA review vouchers to Compass Pathways and two other psychedelic drug companies to fast-track approval for mental illness treatment is framed as a controversial reversal that scientists warn could harm patients due to limited safety data, especially for ibogaine.
I bought the Trump phone..
After a year of delays, misleading customer service, and spam emails, the creator of the Trump Mobile T1 finally received the phone and exposed its shortcomings in a video, claiming it's a $500 scam with misleading 'Made-in-USA' branding and subpar components.